Vivos Therapeutics, Inc. (VVOS) AI Dilution Summary

Cash was $1,774,000 at 2026-06-30 against estimated monthly burn of $1,493,000, funded through an active at-the-market program with H.C. Wainwright & Co., LLC authorised to $5,830,572, with 2,464,585 shares sold through 2026-06-30 and sales after 2026-06-30 not yet reported. The newest listed offering closed 2026-09-02, issuing 11,445,080 shares at $0.2500 per share.